NVP-BEZ235 synergizes cisplatin sensitivity in osteosarcoma
Sign Up to like & getrecommendations! Published in 2018 at "Oncotarget"
DOI: 10.18632/oncotarget.23711
Abstract: Osteosarcoma(OS) remains a major health concern in childhood and adolescence, although cisplatin is one of the gold standard chemotherapeutic drugs in the treatment of OS, chemoresistant to cisplatin is common. Phosphoinositide 3-kinase (PI3K)-Akt-mammalian target of… read more here.
Keywords: bez235; nvp bez235; osteosarcoma; cisplatin sensitivity ... See more keywords
NVP-BEZ235 inhibits thyroid cancer growth by p53- dependent/independent p21 upregulation
Sign Up to like & getrecommendations! Published in 2020 at "International Journal of Biological Sciences"
DOI: 10.7150/ijbs.37592
Abstract: NVP-BEZ235 is a novel dual PI3K/mTOR inhibitor, currently in phase 1/2 clinical trials, exhibiting clinical efficiency in treatment of numerous malignancies including thyroid cancer. Cancer cells harboring mutant p53 was widely reported to be blunt… read more here.
Keywords: thyroid cancer; cancer; p53; upregulation ... See more keywords